Gilead, Merck plan to debut new daily HIV pillsnews2026-02-25T21:01:54+00:00February 25th, 2026|Endpoints News|
Make way, Camzyos: Cytokinetics touts promising early launch for rival heart drugnews2026-02-25T20:17:20+00:00February 25th, 2026|Endpoints News|
Charles River sells its CDMO and European discovery businessesnews2026-02-25T16:22:03+00:00February 25th, 2026|Endpoints News|
Accent axes a cancer study; Werewolf considers its optionsnews2026-02-25T15:38:29+00:00February 25th, 2026|Endpoints News|
Alkermes CEO Richard Pops to retire after 35-year tenurenews2026-02-25T15:28:13+00:00February 25th, 2026|Endpoints News|
States sue Kennedy over US childhood vaccine overhaulnews2026-02-25T14:57:13+00:00February 25th, 2026|Endpoints News|
Novo Nordisk teams with Langer-founded biotech for oral obesity drugsnews2026-02-25T13:00:59+00:00February 25th, 2026|Endpoints News|
Polymer nanoparticle startup BreezeBio raises $60M for mRNA diabetes therapynews2026-02-25T12:00:38+00:00February 25th, 2026|Endpoints News|
Who’s leading LGBTQ+ inclusion in biopharma? Nominate them for Endpoints’ annual reportnews2026-02-25T12:00:13+00:00February 25th, 2026|Endpoints News|
